Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.45)
# 2,200
Out of 5,182 analysts
81
Total ratings
53.01%
Success rate
-2.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Neutral | n/a | $2.57 | - | 3 | Apr 13, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $55 → $37 | $22.14 | +67.12% | 2 | Feb 27, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | n/a | $35.06 | - | 1 | Feb 24, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Overweight | n/a | $30.04 | - | 1 | Dec 23, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $1.84 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $222.08 | +14.37% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $2.51 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $29.04 | - | 3 | Sep 9, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $8.83 | - | 11 | Jun 26, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.90 | - | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $5.06 | - | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.22 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.64 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $24.80 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.69 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.58 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.62 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $4.88 | -38.52% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.30 | +284.62% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.77 | +1,271.84% | 1 | Aug 12, 2022 |
Replimune Group
Apr 13, 2026
Downgrades: Neutral
Price Target: n/a
Current: $2.57
Upside: -
Zai Lab
Feb 27, 2026
Maintains: Overweight
Price Target: $55 → $37
Current: $22.14
Upside: +67.12%
Tyra Biosciences
Feb 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $35.06
Upside: -
ArriVent BioPharma
Dec 23, 2025
Initiates: Overweight
Price Target: n/a
Current: $30.04
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $1.84
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $222.08
Upside: +14.37%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.51
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $29.04
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.83
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.90
Upside: -
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.06
Upside: -
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.22
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.64
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $24.80
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.69
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.58
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.62
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $4.88
Upside: -38.52%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.30
Upside: +284.62%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.77
Upside: +1,271.84%